HC Wainwright Issues Pessimistic Forecast for KROS Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – HC Wainwright lowered their FY2024 EPS estimates for shares of Keros Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($5.36) for the year, down from their previous forecast of ($4.64). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.48) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.57) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.59) EPS, FY2025 earnings at ($6.21) EPS, FY2026 earnings at ($7.15) EPS, FY2027 earnings at ($8.41) EPS and FY2028 earnings at ($5.79) EPS.

KROS has been the topic of a number of other research reports. Wedbush restated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They issued an “overweight” rating on the stock. Guggenheim assumed coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Finally, Scotiabank assumed coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $64.88 on Monday. The company has a market cap of $2.43 billion, a PE ratio of -13.08 and a beta of 1.23. Keros Therapeutics has a one year low of $27.31 and a one year high of $73.00. The firm’s 50 day simple moving average is $58.65 and its 200 day simple moving average is $52.23.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the company posted ($1.33) EPS. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after purchasing an additional 251 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares in the last quarter. KBC Group NV increased its stake in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Arizona State Retirement System increased its stake in Keros Therapeutics by 16.3% during the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares in the last quarter. Finally, American International Group Inc. increased its stake in Keros Therapeutics by 13.1% during the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock valued at $838,000 after purchasing an additional 1,465 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.